Anika Klaus
Berlin, BE 13353, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy.
Journal: Pharmacological research
Published: October 20, 2024
Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Journal: Frontiers in immunology
Published: August 19, 2022
Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis.
Journal: Cancers
Published: September 27, 2021
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Journal: Journal for immunotherapy of cancer
Published: June 18, 2021
A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization.
Journal: Frontiers in immunology
Published: April 01, 2021
Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Journal: Molecular carcinogenesis
Published: January 15, 2020
Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy.
Journal: Frontiers in immunology
Published: December 13, 2019
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
Journal: Annals of the rheumatic diseases
Published: April 13, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026